Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

522 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lower respiratory tract infections remain one of the leading causes of death worldwide. Increasing rates of antibiotic resistance and newer, more pervasive pneumonia-causative pathogens contribute to this statistic. Currently available macrolide antibiotics for the treatment of community-acquired pneumonia are slowly losing effectiveness, resulting in the need to develop newer drugs to fight resistant infections. In this study, we compare the safety and efficacy of a common macrolide, clarithromycin, to a new ketolide, cethromycin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pneumonia Respiratory Infection Infectious Advanced Life Sciences Lung Pulmonary Cethromycin Clarithromycin Biaxin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cethromycin

Group Type EXPERIMENTAL

Cethromycin

Intervention Type DRUG

Cethromycin 300 mg once per day (QD) for 7 days, administered orally

Clarithromycin

Group Type ACTIVE_COMPARATOR

Clarithromycin

Intervention Type DRUG

Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cethromycin

Cethromycin 300 mg once per day (QD) for 7 days, administered orally

Intervention Type DRUG

Clarithromycin

Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Restanza ABT-773 Biaxin Klacid Klaracid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ambulatory male or female, 18 years of age or older
* If female, non-lactating and at no risk or pregnancy (post-menopausal or must use adequate birth control)
* Positive Chest X-ray consistent with diagnosis of bacterial pneumonia
* Must be a suitable candidate for oral antibiotic therapy and must be able to swallow capsules intact
* Recent history of respiratory illness consistent with the clinical signs and symptoms of bacterial CAP
* Must be able to produce sputum

Exclusion Criteria

* Prior hospitalization within previous 4 weeks
* Residence at a chronic care facility
* Active tuberculosis (or other mycobacterial infection, empyema, lung abscess, pulmonary embolism, pulmonary edema, cystic fibrosis, tumor (primary or metastatic) involving the lung, bronchial obstruction, a history of post-obstructive pneumonia (Chronic Obstructive Pulmonary Disease \[COPD\] is not exclusionary), known or suspected Pneumocystis carinii pneumonia
* Treatment with long-acting antimicrobial agents within the last 4 weeks, treatment with ceftriaxone, azithromycin or dirithromycin antibiotic within the last 7 days, or subjects who have received more than 24 hours of treatment with other antibiotics within 7 days prior to study drug administration
* Any infection which requires the use of a concomitant antimicrobial agent
* History of hypersensitivity or allergic reactions to macrolide, ketolide, quinolone, azalide or streptogramin antimicrobials
* Treatment with another investigational drug within the last 4 weeks
* Females who are pregnant or lactating
* Subjects with known significant renal or hepatic impairment or disease
* Subjects with a history of impaired renal function
* Evidence of uncontrolled clinically significant cardiovascular, pulmonary, metabolic, gastrointestinal, neurological or endocrine disease, malignancy, or other abnormality (other than the disease being studied)
* Subjects who would require parenteral antimicrobial therapy for the treatment of pneumonia
* Any underlying disease or condition that would interfere with the completion of the study procedures and evaluations or absorption of the study drug
* Currently receiving or are likely to require any of the following medications during the period between 2 weeks prior to Evaluation 1 and within 24 hours after the last dose of study drug: astemizol (Hismanal®) or pimozide (Orap®)
* Currently receiving or are likely to require any of the following during the period from Evaluation 1 and within 24 hours after the last dose of study drug: theophylline or theophylline analogues (unless adequately monitored), carbamazepine, dexamethasone, phenobarbital, phenytoin, St. John's Wort, lamotrigine, troglitazone, warfarin and digitalis glycoside. Other barbiturates may be used with careful monitoring
* Subjects who are currently receiving or who are likely to require any of the following medications during the period between Evaluation 1 and 4: other systemic antibiotic therapy, rifampin or rifabutin
* Immunocompromised subjects, subjects receiving immunosuppressive agents, subjects with known human immunodeficiency virus (HIV) infections and history of acquired immune deficiency syndrome (AIDS) defining conditions or CD4+ T-lymphocyte count \<200.
* Subject with known or suspected central nervous system (CNS) disorder that predisposes them to seizures/lower seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy)
* Previous treatment with cethromycin
* Subjects with signs of septic shock (e.g., mental confusion, severe hypoxemia, severe hypotension, any other condition requiring intensive care unit \[ICU\] admission)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Advanced Life Sciences

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David A. Eiznhamer, PhD.

Role: STUDY_DIRECTOR

Advanced Life Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.